The market has climbed 1.6% in the last 7 days and is up 19% over the last 12 months, with earnings forecast to grow by 18% annually. For investors willing to explore beyond the big names, penny stocks — often smaller or newer companies — can be full of surprises. While the term might evoke earlier market trends, these stocks can provide a mix of affordability and growth potential when paired with strong financials.

Let's take a closer look at a couple of our picks from the screened companies.

HF Foods Group (HFFG)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: HF Foods Group Inc. operates as a marketer and distributor of specialty food products, including seafood, fresh produce, frozen and dry foods, as well as non-food items to Asian restaurants and other foodservice customers in the United States, with a market cap of $97.33 million.

Operations: The company generates $1.24 billion in revenue from the sale of food and non-food products.

Market Cap: $97.33M

HF Foods Group Inc., with a market cap of US$97.33 million, recently experienced significant changes, including its removal from multiple Russell indices and the appointment of Taylor S. Brown to its board. Despite generating US$1.24 billion in revenue, the company remains unprofitable with a negative return on equity of -17.8%. While HF Foods has sufficient cash runway for over three years and short-term assets exceeding liabilities, it faces challenges such as high net debt to equity ratio (74.4%) and increasing losses over five years at 66.4% annually, contributing to its penny stock status amidst volatility concerns.

ProKidney (PROK)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: ProKidney Corp. is a clinical-stage biotechnology company focused on developing cell therapies for chronic kidney diseases in the United States, with a market cap of approximately $613.18 million.

Operations: ProKidney's revenue is derived entirely from its biotechnology startups segment, totaling $0.89 million.

Market Cap: $613.18M

ProKidney Corp., with a market cap of US$613.18 million, is a pre-revenue biotech firm focused on cell therapies for chronic kidney diseases. Despite its unprofitability and negative return on equity of -59.4%, the company has no debt and sufficient cash runway exceeding one year based on current free cash flow. Recent additions to multiple Russell indices reflect increased visibility within investment circles, potentially enhancing liquidity and investor interest. However, challenges remain as losses have grown by 13.7% annually over five years, with profitability not expected in the near term despite forecasted revenue growth of 63.05% per year.

SIGA Technologies (SIGA)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: SIGA Technologies, Inc. is a commercial-stage pharmaceutical company specializing in the health security market in the United States, with a market cap of $276.86 million.

Operations: The company generates revenue primarily from its Pharmaceuticals segment, totaling $93.78 million.

Market Cap: $276.86M

SIGA Technologies, with a market cap of US$276.86 million, faces challenges as it transitions within the Russell indices, moving to defensive categories from growth benchmarks. Despite reporting first-quarter revenue of US$6.24 million and a net loss of US$3.45 million, SIGA remains debt-free with strong short-term asset coverage over liabilities. The company trades at 17.7% below estimated fair value and has experienced management and board teams, though recent earnings have declined by 0.7% annually over five years. While profit margins have decreased from last year’s levels, forecasts suggest potential earnings growth of 94.06% per year ahead.

Turning Ideas Into Actions

• Discover the full array of 322 US Penny Stocks right here.
• Looking For Alternative Opportunities? Rare earth metals are the new gold rush. Find out which 31 stocks are leading the charge.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.